The first domestic PD-L1 monoclonal antibody is about to be approved

On November 24, the domestic market application of AstraZeneca’s PD-L1 Durvalumab injection (Imfinzi) was under “approval” status. It is expected that it will soon be approved as the first domestically marketed PD-L1 monoclonal antibody drug for Treatment of inoperable stage III non-small cell lung cancer.

500 million anti-allergic drugs welcome reviewers again

On the evening of November 24, Hainan Puli Pharmaceutical issued an announcement stating that the company had recently received the "Approval for Drug Supplement Application" for desloratadine tablets ( 5mg ) issued by the State Food and Drug Administration, and the product passed the consistency evaluation. According to data from Menet.com, the market for terminal systemic antihistamines in public medical institutions in China was 4.906 billion yuan in 2018, and currently only three varieties have been reviewed by companies.

Roche’s “ Pertuzumab ” 3rd indication will be approved soon

On November 22, Roche’s innovative breast cancer targeted drug Perjet® (English trade name: Perjeta®, generic name: Pertuzumab) for new indications for marketing application (acceptance number JXSS1800042) changed its status to Approval, this will be the third indication approved by Pathet in the Chinese market after it was first approved for listing last year.